BioCryst Pharmaceuticals jumps as investors revisit profitable 2025 results, upbeat HAE pipeline data, and potential short-covering dynamics

BioCryst Pharmaceuticals (BCRX) is up 13.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The move looks most consistent with a momentum follow-through from BioCryst’s late-February business update that highlighted a first profitable year, maintained 2026 ORLADEYO revenue guidance, and reiterated positive longer-term data for navenibart in HAE. With notable short interest in the stock, part of today’s upside could be because incremental buying pressure triggered short covering.

Details:

BioCryst reported full-year 2025 ORLADEYO net revenue of about $602 million and highlighted record operating profitability, reinforcing a “commercial execution” narrative for its HAE franchise.

The company maintained 2026 ORLADEYO net revenue guidance of $625–$645 million (and total revenue guidance of $635–$660 million), which can support re-rating when investors gain confidence in forward-year visibility.

BioCryst highlighted interim long-term navenibart (HAE prophylaxis) results showing durable attack-rate reductions with dosing every three or six months, and said it expected those data to be featured as a late-breaking presentation at a major allergy/immunology meeting.

This stock also carried elevated short interest in the latest reporting period (roughly mid-teens as a percent of shares outstanding), which can amplify upside moves when sentiment improves.

Sources:

BioCryst Pharmaceuticals, SEC, StockAnalysis.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$BCRX Insider Trading Activity

$BCRX insiders have traded $BCRX stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.

Here’s a breakdown of recent trading of $BCRX stock by insiders over the last 6 months:

ALANE P BARNES (Chief Legal Officer) has made 0 purchases and 5 sales selling 204,663 shares for an estimated $1,493,786.
MACHELLE SANDERS sold 9,600 shares for an estimated $68,544

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

$BCRX Hedge Fund Activity

We have seen 135 institutional investors add shares of $BCRX stock to their portfolio, and 193 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

RA CAPITAL MANAGEMENT, L.P. added 15,827,186 shares (+inf%) to their portfolio in Q4 2025, for an estimated $123,452,050
JANUS HENDERSON GROUP PLC added 7,310,745 shares (+7807.2%) to their portfolio in Q4 2025, for an estimated $57,023,811
ALKEON CAPITAL MANAGEMENT LLC removed 5,464,021 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $42,619,363
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 5,159,742 shares (-98.7%) from their portfolio in Q4 2025, for an estimated $40,245,987
HOOD RIVER CAPITAL MANAGEMENT LLC removed 3,620,261 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $28,238,035
MORGAN STANLEY removed 3,457,396 shares (-66.5%) from their portfolio in Q4 2025, for an estimated $26,967,688
PERCEPTIVE ADVISORS LLC added 3,162,529 shares (+inf%) to their portfolio in Q4 2025, for an estimated $24,667,726

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$BCRX Government Contracts

We have seen $776,431 of award payments to $BCRX over the last year.

Here are some of the awards which we have have seen pay out the most over the last year:

BULK ORDER ORLADEYO FOR VETERAN CARE.: $382,300
PHARM - ORLADEYO: $360,000
BEROTRALSTAT HCL 150MG CAP,ORAL (ORLADEYO).: $34,130

To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.

$BCRX Congressional Stock Trading

Members of Congress have traded $BCRX stock 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.

Here’s a breakdown of recent trading of $BCRX stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. purchased up to $15,000 on 11/13.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

$BCRX Analyst Ratings

Wall Street analysts have issued reports on $BCRX in the last several months. We have seen 5 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

RBC Capital issued a "Outperform" rating on 01/30/2026
Citizens issued a "Market Outperform" rating on 11/05/2025
Needham issued a "Buy" rating on 11/04/2025
TD Cowen issued a "Buy" rating on 10/15/2025
Cantor Fitzgerald issued a "Overweight" rating on 10/15/2025

To track analyst ratings and price targets for $BCRX, check out Quiver Quantitative's $BCRX forecast page.

$BCRX Price Targets

Multiple analysts have issued price targets for $BCRX recently. We have seen 8 analysts offer price targets for $BCRX in the last 6 months, with a median target of $25.5.

Here are some recent targets:

Brian Abrahams from RBC Capital set a target price of $13.0 on 01/30/2026
Andrew S. Fein from HC Wainwright & Co. set a target price of $32.0 on 12/15/2025
Jonathan Wolleben from Citizens set a target price of $25.0 on 11/05/2025
Serge Belanger from Needham set a target price of $18.0 on 11/04/2025
Gena Wang from Barclays set a target price of $9.0 on 11/04/2025
Stacy Ku from TD Cowen set a target price of $30.0 on 10/15/2025
Steven Seedhouse from Cantor Fitzgerald set a target price of $26.0 on 10/15/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.